Plain-English translation of NCT07744932 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a three-part treatment approach for a specific type of kidney cancer (clear cell renal cell carcinoma) that has spread to 5 or fewer locations in the body. The combination includes a precise radiation therapy called SABR, an oral targeted cancer drug called axitinib, and an immunotherapy drug called toripalimab. Researchers want to see if using all three treatments together helps shrink or eliminate tumors better than previous approaches.
Kidney cancer that has spread to only a few sites presents a unique opportunity — it may be possible to treat all the cancer spots with strong local therapy. This trial exists to test whether combining the radiation therapy with this medication can improve how well the treatment works and how long patients survive.
You likely qualify if…
You likely don't qualify if…
You would receive 5 sessions of targeted radiation therapy to all your cancer spots over about 2 weeks, while also taking an oral medication twice daily and receiving an intravenous immunotherapy infusion every 3 weeks. This combined treatment would continue for up to 2 years, with regular imaging scans, blood tests, and check-ins to monitor how you're doing and watch for any side effects. You'll also complete quality-of-life surveys throughout your participation to help researchers understand the full impact of the treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China